PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Doravirine→

Doravirine PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1338225-97-0
Molecular formula
C17H11ClF3N5O3
Molecular weight
425.7 g/mol
Drug class
Non-nucleoside reverse transcriptase inhibitor (NNRTI)antiretroviral
Mechanism of action
Directly binds HIV-1 reverse transcriptase at an allosteric site, inhibiting RNA- and DNA-dependent DNA polymerase activity and preventing viral replication.
Indications / reported uses
  • Treatment of HIV-1 infection in adults and eligible adolescents as part of combination antiretroviral therapy, in patients without known resistance-associated substitutions to doravirine; not used as monotherapy

Sources: US DailyMed — PIFELTRO (doravirine) · US DailyMed — DELSTRIGO (doravirine/lamivudine/tenofovir disoproxil fumarate) · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Doravirine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Doravirine Permitted Daily Exposure (PDE) report (the Doravirine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Doravirine Occupational Exposure Limit (OEL) report (the Doravirine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.